Fior Markets launched a study titled “Global Flow Cytometry Market by Technology (Cell-Based Flow Cytometry, Bead-Based Flow Cytometry), Product & Service, Application, End-Users, Region” and Global Forecast 2018-2025.
The global flow cytometrymarket is expected to reach USD 4,100.92Million in 2017 to USD 8,590.71 Million by 2025 at a CAGR of 9.60%during the forecast periodfrom 2018-2025. Advantages of flow cytometry assays such high sensitivity & reproductively and availability of software used for the analysis are driving the growth of the market in the assessment period.
DOWNLOAD FREE SAMPLE REPORT:https://www.fiormarkets.com/report-detail/375978/request-sample
The bead-based technology segment held the largest market share and was valued around USD 2,214.72 million in 2017
The technologysegment is divided into cell-based and bead-based flow cytometry.The bead-based technology segment held the largest market share and was valued around USD 2,214.72 million in 2017. Cell-based technology offers advantages including its capacity to detect multiple analytes, high reproducibility, stability, and speed.
Reagents and consumables segment is dominating and held the largest market share of 47.28% in 2017
The product and service segment is classified into reagents and consumables, instruments, services, software and accessories. Reagents and consumablessegment is dominatingand held the largest market share of 47.28% in 2017. Requirement and commercialization of high-quality application-specific reagents and assays by end users is supporting the growth of the segment.
Research segment is growing with the highest CAGR of 12.07% in the forecast period
Application segment includes research applications, clinical applications and industrial applications. Research segment is expected to grow at lucrative CAGR of 12.07% in the forecast period. Increasing R&D pertaining to cancer and other infectious diseases and various applications in several industries such as food microbiology and plant tissue culture are driving the growth of the segment.
Hospitals segment is expected to dominate and was valued around USD 1,804.73 million in 2017
End user segment is categorised intoacademic and research institutes, hospitals & clinical testing laboratories and pharmaceutical & biotechnology companies.Hospitals segment is expected to dominate and was valued around USD 1,804.73 million in 2017. Increasing diagnostic tests rising, prevalence of chronic and infectious diseases and growing awareness are contributing to the growth of the segment.
BROWSE COMPLETE REPORT AND TABLE OF CONTENTS:https://www.fiormarkets.com/report/global-flow-cytometry-market-by-technology-cell-based-flow-375978.html
Regional Segmentation Analysis:
The market is analysed on the basis of five regions namely North America, Europe, Asia Pacific, South America, and Middle East and Africa. North Americaregion dominated the marketand was valued around USD 1,968.38 Million in 2017. Presence of supportive government reforms, advanced technologies for molecular diagnostics and availability of skilled professionals in the region.
Some of the major industry players in the market are Thermo Fisher Scientific, Agilent Technologies, SysmexPartec, Apogee Flow Systems, Stratedigm, Beckman Coulter, Sony Biotechnology, Becton, Dickinson and Company, MiltenyiBiotec, Biomérieux S.A., Merck KGaA, Bio-Rad Laboratories, Cytonome St, Enzo Life Sciences, Luminexand others.